Compare EJH & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EJH | AIMD |
|---|---|---|
| Founded | 2018 | 1984 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 16.9M |
| IPO Year | 2021 | N/A |
| Metric | EJH | AIMD |
|---|---|---|
| Price | $0.79 | $2.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 95.7K | 38.4K |
| Earning Date | 12-29-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,402,956.00 | $113,037.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 178.19 |
| 52 Week Low | $0.74 | $1.78 |
| 52 Week High | $64.00 | $5.00 |
| Indicator | EJH | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 37.86 | 42.92 |
| Support Level | $0.78 | $2.12 |
| Resistance Level | $0.87 | $2.29 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 4.71 | 59.62 |
E-Home Household Service Holdings Ltd is a household service company providing integrated household services through its website and WeChat platform across China. The company offers services including home appliance and housekeeping services. It operates its business mainly by receiving orders online and providing services offline. Its operations are organized into four reportable segments: appliance installation and maintenance services, housekeeping services, senior care services, and educational consulting services. The company generates the majority of its revenue from installation and maintenance.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.